Methylprednisolone acetate immune suppression produces differing effects on Cryptosporidium muris oocyst production

Thomas A Miller1, Frank W Schaefer

  • 1US Environmental Protection Agency, 26 West Martin Luther King Drive, Cincinnati, OH 45268, United States.

Veterinary Parasitology
|August 28, 2007
PubMed

Insights

Methylprednisolone acetate (MPA) immunosuppression impacts Cryptosporidium muris oocyst shedding based on timing. Early immunosuppression significantly extends shedding, while later suppression has minimal effects, highlighting lymphocyte roles in infection control.

Area of Science:

  • Immunology
  • Parasitology
  • Infectious Diseases

Background:

  • Cryptosporidium muris is an opportunistic protozoan parasite.
  • The role of host immune responses, particularly T- and B-lymphocytes, in controlling C. muris infection is not fully understood.
  • Methylprednisolone acetate (MPA) is a potent immunosuppressive drug.

Purpose of the Study:

  • To investigate the impact of MPA-induced immunosuppression on the course of C. muris infection in mice.
  • To determine how the timing of immunosuppression initiation affects oocyst shedding and parasite persistence.
  • To elucidate the role of T- and B-lymphocytes in managing C. muris infection at different stages.

Main Methods:

  • CF-1 female mice were inoculated with C. muris.
  • Mice received a single dose of MPA (600 mg/kg) at various time points relative to oocyst production (before, during, after).
  • Oocyst shedding, lymphocyte counts (CD3, CD4, CD8 T-lymphocytes, B-lymphocytes), and infection persistence were monitored.

Main Results:

  • MPA immunosuppression significantly reduced T- and B-lymphocyte populations for over 14 days.
  • Initiating immunosuppression before or during oocyst production delayed onset, extended shedding duration, and increased daily oocyst output.
  • Immunosuppression during oocyst decline or after shedding ceased had minimal impact on oocyst production, though infection persisted.
  • Oocyst shedding consistently halted between days 45 and 53 post-inoculation, regardless of immunosuppression timing.

Conclusions:

  • The effect of MPA immunosuppression on C. muris infection is highly dependent on the host's immune status at the time of administration.
  • T- and B-lymphocytes play a critical role in controlling C. muris during the active oocyst production phase.
  • Suppression of lymphocytes later in the infection suggests they are less critical for maintaining immune control after oocyst shedding declines.
  • C. muris infection persists in mice even after oocyst shedding becomes undetectable.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...